Celsion Corporation (CLSN) News
Filter CLSN News Items
CLSN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CLSN News Highlights
- For CLSN, its 30 day story count is now at 7.
- Over the past 20 days, the trend for CLSN's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about CLSN are DNA, DRUG and LE.
Latest CLSN News From Around the Web
Below are the latest news stories about CELSION CORP that investors may wish to consider to help them evaluate CLSN as an investment opportunity.
Celsion Corporation Announces Company Name Change to Imunon, Inc.New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, today announced a company name change to Imunon, Inc., reflecting the evolution of the Company’s business focus and its commitment to developing cutting-edge immunotherapies and next-generation vaccines to treat cancer and infectious diseases. The Co |
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that its Phase I/II OVATION 2 Study with GEN-1 in advanced ovarian cancer has completed enrollment with 110 patients. GEN-1 is the Company’s IL-12 gene-mediate |
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 13th at 4:30 p.m. Eastern time. The presentation will available live and on-demand here. As previously announced, the conference will be held September 12-14 with in-person particip |
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceLAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference. The hybrid conference will be held from September 12-14 with in-person participation held at the Lotte New York Palace Hotel. Dr. Le Goff will pre |
H.C. Wainwright Keeps Their Buy Rating on Celsion (CLSN)E ratio of -0.15. |
Celsion Corporation Highlights Progress in its DNA-based Vaccine ProgramPLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today provided an update on the progress made in the development of a DNA-based vaccine using its PLACCINE platform technology. Additional data from its completed proof-of-concept mouse challenge study confirms that a PLACCINE vaccine can produce |
CLSN: Complete Enrollment of OVATION 2 Study Expected in 3Q22…By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT Business Update OVATION 2 Enrollment Expected to Complete in 3Q22 Celsion Corporation (NASDAQ:CLSN) is currently conducting the Phase 1/2 OVATION 2 study of GEN-1 (the company’s lead immunotherapy development product) in advanced stage (Stage III/IV) ovarian cancer. The company recently announced that 106 patients are currently |
Analysts Conflicted on These Healthcare Names: Celsion (CLSN), Aileron Therapeutics (ALRN) and Monopar Therapeutics Inc (MNPR)Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Celsion (CLSN – Research Report), Aileron Therapeutics (ALRN – Research Report) and Monopar Therapeutics Inc (MNPR – Research Report). Celsion (CLSN) In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on Celsion, with a price target of $16.00. The company's shares closed last Monday at $2.54, close to its 52-week low of $1.80. According to TipRanks.com, Bodnar is a 4-star analyst with an average return of -9.7% and a 28.7% success rate. |
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business UpdateDNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, today announced financial results for the three and six months ended June 30, 2022, and provided an update on its clinical development program of GEN- |
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, August 15, 2022 to discuss financial results for the second quarter ended June 30, 2022 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for |